Related Experiment Video
Updated: Jun 23, 2026

Isolation of Functional Cardiac Immune Cells
Published on: December 5, 2011
Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart
Scott P Levick1, Jennifer L McLarty, David B Murray
1Department of Cell Biology and Anatomy, School of Medicine, University of South Carolina, Columbia, SC 29208, USA.
Insights
Cardiac mast cell activation causally links to fibrosis in hypertensive hearts. Nedocromil treatment inhibited this fibrosis by reducing mast cell products like tryptase and regulating inflammatory cytokines.
Area of Science:
- Cardiovascular Research
- Immunology
- Pharmacology
Background:
- Cardiac mast cells are implicated in hypertension-induced myocardial remodeling.
- A direct causal link between mast cell activation and fibrosis in hypertension remains unestablished.
Purpose of the Study:
- To investigate the causal role of mast cell activation in hypertension-induced cardiac fibrosis.
- To determine if inhibiting mast cell product release prevents adverse myocardial remodeling.
Main Methods:
- Spontaneously hypertensive rats were treated with nedocromil, a mast cell stabilizer.
- Cardiac fibrosis, mast cell density, tryptase levels, and inflammatory cytokines were assessed.
- Cardiac fibroblasts were treated with tryptase to evaluate collagen synthesis.
Main Results:
- Nedocromil prevented left ventricular fibrosis independently of blood pressure and hypertrophy.
- Tryptase levels were elevated in hypertensive rats and normalized by nedocromil.
- Tryptase induced collagen synthesis in cardiac fibroblasts, and nedocromil reduced macrophage infiltration and modulated cytokine profiles.
Conclusions:
- Mast cell activation causally contributes to cardiac fibrosis in hypertension.
- Tryptase, inflammatory cell recruitment, and cytokine dysregulation are key mechanisms mediating this fibrosis.
Abstract:
Correlative data suggest that cardiac mast cells are a component of the inflammatory response that is important to hypertension-induced adverse myocardial remodeling. However, a causal relationship has not been established. We hypothesized that adverse myocardial remodeling would be inhibited by preventing the release of mast cell products that may interact with fibroblasts and other inflammatory cells. Eight-week-old male spontaneously hypertensive rats were treated for 12 weeks with the mast cell stabilizing compound nedocromil (30 mg/kg per day). Age-matched Wistar-Kyoto rats served as controls. Nedocromil prevented left ventricular fibrosis in the spontaneously hypertensive rat independent of hypertrophy and blood pressure, despite cardiac mast cell density being elevated. The mast cell protease tryptase was elevated in the spontaneously hypertensive rat myocardium and was normalized by nedocromil. Treatment of isolated adult spontaneously hypertensive rat cardiac fibroblasts with tryptase induced collagen synthesis and proliferation, suggesting this as a possible mechanism of mast cell-mediated fibrosis. In addition, nedocromil prevented macrophage infiltration into the ventricle. The inflammatory cytokines interferon-gamma and interleukin (IL)-4 were increased in the spontaneously hypertensive rat and normalized by nedocromil, whereas IL-6 and IL-10 were decreased in the spontaneously hypertensive rat, with nedocromil treatment normalizing IL-6 and increasing IL-10 above the control. These results demonstrate for the first time a causal relationship between mast cell activation and fibrosis in the hypertensive heart. Furthermore, these results identify several mechanisms, including tryptase, inflammatory cell recruitment, and cytokine regulation, by which mast cells may mediate hypertension-induced left ventricular fibrosis.
Related Concept Videos
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Myocarditis I: Introduction
Rheumatic Heart Disease I: Introduction
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
